Moderna says Covid-19 vaccine also generates antibodies among elderly

Moderna shares found a bid in the middle of the week after the biotechnology outfit announced that its experimental Covid-19 vaccine did generate antibodies against the disease in elderly patients.

It was the first time that the firm had disclosed data on the vaccine's performance for all age groups participating in a clinical study.

The finding was significant due to the uncertainty among members of the scientific community regarding whether that would be the case, with potentially significant implications when it came to plans to inoculate a large percentage of the population.

Moderna's senior vice-president, Dr.Jaqueline Miller, said that neutralising antibody titers were registered in all age groups, 18-55, 56-70 and for those 71 and older.